As long as there isn't some massive convertible note in the works. These bio-pharmas are tricky. At least MEDIF is racking up huge revenue streams as seen in recent earnings.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.